Researchers from the HIV Prevention Trials Network (HPTN) have presented results from the HPTN 094 ("INTEGRA") study at the ...
Gilead's CROI 2025 data highlights Biktarvy's sustained HIV/HBV suppression, lenacapavir's efficacy, and vesatolimod's safety ...
The advent of effective antiretroviral therapy (ART) has increased the lifespan of many people living with HIV. As a result, ...
Researchers led by Imperial have unveiled primary trial results that show encouraging advances in HIV treatment driven by ...